Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs: a Dutch database study

Yvonne van der Zalm*, Fabian Termorshuizen, Iris E. Sommer, Jean-Paul Selten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Downloads (Pure)

Abstract

Reports of decreased mortality among patients with schizophrenia who use clozapine may be biased if clozapine is prescribed to relatively healthy patients and if intensive monitoring during its use prevents (under-treatment of) somatic disorder. We aimed to assess whether there is a difference in: (1) somatic comorbidity between patients who start with clozapine and those who start with other antipsychotics and (2) prescribed somatic medication, between patients using clozapine and those using olanzapine. Cohort study based on insurance claims (2010-2015). After selecting new users of antipsychotics and those who subsequently switched to clozapine (N = 158), aripiprazole (N = 295), olanzapine (N = 204) or first-generation antipsychotics (N = 295), we compared the clozapine starters to others on cardiovascular or diabetic comorbidity. Those using clozapine and olanzapine were compared on new prescriptions for cardiovascular or antidiabetic drugs. The OR(adj)of cardiovascular or diabetic comorbidity among other starters compared with clozapine starters was 0.77 [95% confidence interval (CI): 0.43-1.39], that is, a nonsignificantly increased prevalence associated with clozapine was found. Users of clozapine received significantly more new prescriptions for cardiovascular or antidiabetic medication (ORadj: 2.70, 95% CI: 1.43-5.08). Starters with clozapine were not cardiovascular/metabolic healthier than starters with other antipsychotics. During its use, they received more somatic treatment.

Original languageEnglish
Pages (from-to)36-41
Number of pages6
JournalInternational Clinical Psychopharmacology
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 2020

Keywords

  • clozapine
  • epidemiology
  • outpatients
  • schizophrenia
  • 2ND-GENERATION ANTIPSYCHOTICS
  • SCHIZOPHRENIA
  • MORTALITY
  • SAFETY
  • TOLERABILITY
  • EFFICACY

Cite this